Patient Hub Redesign Drives 25% Improvement in Adherence Rates

Background and Challenge

A specialty pharmaceutical company with a leading oncology supportive care product (OncoGuard, a once-daily oral medication for chemotherapy-induced nausea and vomiting) faced a growing adherence crisis that was eroding the brand's commercial performance. Despite strong clinical efficacy data and high initial prescribing enthusiasm from oncologists, patient persistency was declining sharply: 40% of patients who started OncoGuard had discontinued therapy within six months of initiation.

The company operated a patient support hub, but it was a bare-bones operation that functioned primarily as a copay card processor and benefits investigation service. The hub's engagement model was reactive: it responded to inbound calls from patients and healthcare providers but did not proactively reach out to patients at critical points in their treatment journey. The hub had limited digital capabilities (no patient portal, no mobile app, no automated messaging), no personalized patient communication, and no data integration with specialty pharmacies or electronic health records.

The consequences of poor adherence were significant for both patients and the brand. Chemotherapy-induced nausea and vomiting is a debilitating condition that affects treatment quality, nutritional status, and patients' willingness to continue chemotherapy. Patients who did not take OncoGuard as prescribed experienced worse outcomes, which in turn led physicians to question the product's effectiveness and consider switching to competitors. From a commercial perspective, the 40% six-month drop-off rate was estimated to cost the brand $45 million in annual lost revenue from prescriptions that were written but never filled or abandoned prematurely.

"We had a patient hub that processed copay cards and answered phone calls. That was it. We were spending $3.2 million a year on a hub that was essentially a call center. Meanwhile, 40% of our patients were dropping off therapy within six months and we were doing nothing to intervene." — Head of Patient Access and Engagement

The brand team set an ambitious goal: redesign the patient hub from a reactive call center into a proactive, digital-first patient engagement platform that would improve 90-day adherence rates by at least 20% and reduce time-to-therapy (the interval between prescription written and first fill) by at least 25%.

The Approach

The hub redesign was structured as a 15-month initiative in three phases: patient journey mapping and design, technology platform build and integration, and pilot launch with iterative optimization.

Phase 1: Patient Journey Mapping and Design (Months 1-4)

The team began with an intensive patient journey mapping exercise to understand the specific barriers, emotions, and decision points that patients experienced from the moment an OncoGuard prescription was written through the first six months of therapy. They conducted 45 in-depth interviews with current and lapsed patients, surveyed 200 patients across the persistency spectrum, and interviewed 25 oncology nurses and pharmacists who interacted with patients during chemotherapy cycles.

The journey mapping revealed five critical drop-off points where patients were most likely to disengage:

1. Prescription to first fill (days 0-7): 18% of patients who received a prescription never filled it. The primary barriers were prior authorization delays (averaging 5.3 days), confusion about how to use the copay card, and inability to navigate the specialty pharmacy process.
2. First fill to second fill (days 14-30): 12% of patients who filled their first prescription did not fill a second. The primary barriers were side effect concerns (mild headache and fatigue in the first week), lack of understanding about when to take the medication relative to chemotherapy cycles, and cost confusion after the copay card was exhausted for the initial fill.
3. Chemotherapy gap periods (days 30-90): 15% of patients stopped during the gap between chemotherapy cycles, often because they did not understand that OncoGuard should be continued between cycles to maintain therapeutic levels.
4. Month 3-4 fatigue (days 60-120): 8% of patients discontinued during months 3-4, often due to cumulative treatment fatigue and a sense that the medication was not needed if nausea was controlled (a paradox where effective treatment led to perceived lack of need).
5. Month 5-6 financial re-engagement (days 120-180): 7% of patients dropped off when annual copay card limits were reached or when insurance reauthorization was required, creating a financial and administrative barrier.

Based on these findings, the design team created a personalized patient engagement framework with five intervention modules, each targeting a specific drop-off point with tailored content and channel delivery.

Phase 2: Digital Platform Build and Integration (Months 5-10)

The technology build focused on four capabilities that the existing hub lacked:

1. Digital-First Intake and Enrollment. The team built a mobile-responsive patient portal that allowed patients to enroll in the support program digitally, upload insurance information, activate their copay card, and schedule their first nurse navigator call, all in a single session that took less than 5 minutes. This replaced the previous enrollment process, which required patients to call a 1-800 number during business hours, navigate a phone tree, and verbally provide information to a call center agent who manually entered it into a CRM system.

2. Automated Trigger-Based Communication. The platform integrated with the specialty pharmacy's fulfillment system to receive real-time notifications when a prescription was received, when it was approved, when it was shipped, and when it was delivered. Each trigger initiated an automated communication to the patient via their preferred channel (SMS, email, or app notification) with relevant, timely information about their prescription status and next steps. This replaced the previous approach of waiting for patients to call the hub to check on their prescription status.

3. Nurse Navigator Program. The team hired and trained 8 oncology-certified nurse navigators (up from 3 general call center agents) who provided proactive clinical support to patients at key moments: a welcome call within 24 hours of enrollment, a side effect management call at day 5 after first fill, a chemotherapy cycle alignment call before each new cycle, and an adherence check-in at day 60 and day 90. The nurse navigators were empowered to address clinical questions, coordinate with the patient's oncology team, and provide personalized counseling on the importance of adherence between chemotherapy cycles.

4. Data Integration Layer. The team built data integrations with three specialty pharmacies (which dispensed 85% of OncoGuard prescriptions), the copay card processor, the prior authorization support platform, and the brand's CRM system. This integration created a unified patient record that gave nurse navigators and the automated communication engine complete visibility into each patient's status: whether their prescription had been received, approved, shipped, and delivered; whether they had activated their copay card; and whether they were due for a refill based on their dispense date and days-of-supply.

Phase 3: Pilot Launch and Optimization (Months 11-15)

The redesigned hub was launched as a pilot in three regions (representing 30% of national prescribing volume) for the first three months, with the remaining regions served by the legacy hub as a control group. This pilot design allowed the team to measure the impact of the new hub against a concurrent control, rather than relying on before-and-after comparisons that could be confounded by seasonal or market effects.

Results

The pilot results exceeded the team's targets across all primary and secondary endpoints:

The 90-day persistency rate improved from 60% to 75%, a 25% relative improvement that exceeded the original target of 20%. The improvement was driven primarily by two interventions: the automated trigger-based communication that addressed the prescription-to-first-fill drop-off (reducing the 18% never-filled rate to 7%), and the nurse navigator calls at day 5 and day 30 that addressed early discontinuation due to side effect concerns and confusion about dosing schedules.

Time to first fill improved from 8.2 days to 5.3 days, a 35% reduction. This was driven by the digital intake process (which eliminated the phone-based enrollment bottleneck), the automated copay card activation (which removed the financial barrier faster), and the prior authorization support integration (which expedited PA submissions and reduced the average PA approval time from 5.3 to 2.8 days).

The patient enrollment rate increased from 38% to 54% because the digital enrollment portal was accessible 24/7 and could be completed in under 5 minutes, compared to the legacy phone-based process that required calling during business hours and spending 15-20 minutes with a call center agent. The higher enrollment rate meant that more patients had access to copay assistance, nurse navigator support, and refill reminders, which in turn drove the adherence improvements.

ROI Calculation

The redesigned hub required a total investment of $5.8 million annually, compared to $3.2 million for the legacy hub, an incremental investment of $2.6 million. The incremental costs included 5 additional nurse navigators ($625K), the digital platform build and licensing ($850K in year one, $400K ongoing), data integration development ($325K one-time), and additional patient communication and content costs ($800K).

The commercial impact was measured by comparing prescription volume in the pilot regions against the control regions during the same period, adjusted for regional baseline trends. The pilot regions showed a 12% increase in TRx volume compared to the control, representing approximately 2,400 incremental prescriptions over the 6-month measurement period. At an average net revenue per prescription of $1,850, this translated to $4.4 million in incremental net revenue over 6 months, or an estimated $8.8 million annualized.

The incremental ROI of 3.4x meant that every additional dollar invested in the hub redesign generated $3.40 in net revenue. The total hub ROI (including the base hub cost) was 3.8x, meaning the entire $5.8 million hub investment generated $22 million in attributable net revenue through improved persistency, faster time to therapy, and higher enrollment rates.

"The nurse navigators were the game changer. The digital platform got patients enrolled faster and activated their copay cards. The automated messages kept them informed about their prescription status. But it was the nurse call at day five, when a patient was experiencing mild side effects and wondering whether this medication was worth it, that made the difference between a patient who continued and a patient who quit." — Patient Access Program Director

Key Takeaways

Following the successful pilot, the redesigned patient hub was rolled out nationally in month 16. The brand team continues to optimize the intervention timing and content based on ongoing patient feedback and persistency data. The hub redesign is being considered as a template for two additional brands in the company's oncology supportive care portfolio, with adaptations for the specific patient journey dynamics of each product.